Sotyktu for plaque psoriasis and Livtencity 200 mg for cytomegalovirus (CMV) infection will be newly listed for reimbursement from the 1st of next month.

GLP-1 receptor agonists (GLP-1 RAs, single-agent therapy, and combination therapy) will be reimbursed for use in combination with basal insulin therapy when a patient’s HbA1c level is 7% or higher, even with the use of metformin combination therapy.

Reimbursement for the macular degeneration drug Beovu will be extended to cover diabetic macular edema, Rinvoq to moderate-to-severe active ulcerative colitis in adults, Cellcept to connective tissue disease-associated interstitial lung disease, and Soliris to optic neuromyelitis optica spe